These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11311218)

  • 21. A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutation affecting cofactor binding.
    Weidensee S; Goettig P; Bertone M; Haas D; Magdolen V; Kiechle M; Meindl A; van Kuilenburg AB; Gross E
    Clin Biochem; 2011 Jun; 44(8-9):722-4. PubMed ID: 21420945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Porcine recombinant dihydropyrimidine dehydrogenase: comparison of the spectroscopic and catalytic properties of the wild-type and C671A mutant enzymes.
    Rosenbaum K; Jahnke K; Curti B; Hagen WR; Schnackerz KD; Vanoni MA
    Biochemistry; 1998 Dec; 37(50):17598-609. PubMed ID: 9860876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W.
    Vreken P; Van Kuilenburg AB; Meinsma R; van Gennip AH
    Hum Genet; 1997 Dec; 101(3):333-8. PubMed ID: 9439663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for defects of dihydropyrimidine degradation by analysis of amino acids in urine before and after acid hydrolysis.
    van Gennip AH; Driedijk PC; Elzinga A; Abeling NG
    J Inherit Metab Dis; 1992; 15(3):413-5. PubMed ID: 1405482
    [No Abstract]   [Full Text] [Related]  

  • 25. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
    van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
    Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma.
    Morel A; Boisdron-Celle M; Fey L; Lainé-Cessac P; Gamelin E
    Clin Biochem; 2007 Jan; 40(1-2):11-7. PubMed ID: 17046731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase.
    Tuchman M; Ramnaraine ML; O'Dea RF
    Cancer Res; 1985 Nov; 45(11 Pt 1):5553-6. PubMed ID: 4053028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency.
    Van Kuilenburg AB; Vreken P; Abeling NG; Bakker HD; Meinsma R; Van Lenthe H; De Abreu RA; Smeitink JA; Kayserili H; Apak MY; Christensen E; Holopainen I; Pulkki K; Riva D; Botteon G; Holme E; Tulinius M; Kleijer WJ; Beemer FA; Duran M; Niezen-Koning KE; Smit GP; Jakobs C; Smit LM; Van Gennip AH
    Hum Genet; 1999 Jan; 104(1):1-9. PubMed ID: 10071185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography.
    Fischer J; Schwab M; Eichelbaum M; Zanger UM
    Genet Test; 2003; 7(2):97-105. PubMed ID: 12885330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [5-fluorouracil and dihydropyrimidine dehydrogenase].
    Kubota T
    Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
    van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
    Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase.
    Ahluwalia R; Freimuth R; McLeod HL; Marsh S
    Clin Chem; 2003 Oct; 49(10):1661-4. PubMed ID: 14500593
    [No Abstract]   [Full Text] [Related]  

  • 33. [Dihydropyrimidine dehydrogenase deficiency].
    Kouwaki M; Wada Y
    Ryoikibetsu Shokogun Shirizu; 1998; (18 Pt 1):490-3. PubMed ID: 9590110
    [No Abstract]   [Full Text] [Related]  

  • 34. Dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil associated toxicity.
    van Kuilenburg AB; Haasjes J; Van Lenthe H; Zoetekouw L; Waterham HR; Vreken P; van Gennip AH
    Adv Exp Med Biol; 2000; 486():251-5. PubMed ID: 11783494
    [No Abstract]   [Full Text] [Related]  

  • 35. Delayed hypersensitivity to 5-fluorouracil associated with reduced dihydropyrimidine dehydrogenase (DPD) activity.
    Duley JA; Nethersell AB
    Adv Exp Med Biol; 1998; 431():147-50. PubMed ID: 9598048
    [No Abstract]   [Full Text] [Related]  

  • 36. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.
    Johnson MR; Wang K; Diasio RB
    Clin Cancer Res; 2002 Mar; 8(3):768-74. PubMed ID: 11895907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil.
    Dobritzsch D; Schneider G; Schnackerz KD; Lindqvist Y
    EMBO J; 2001 Feb; 20(4):650-60. PubMed ID: 11179210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.
    Johnson MR; Hageboutros A; Wang K; High L; Smith JB; Diasio RB
    Clin Cancer Res; 1999 Aug; 5(8):2006-11. PubMed ID: 10473079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls.
    Innocenti F; Ratain MJ
    Clin Cancer Res; 2002 May; 8(5):1314; author reply 1315-6. PubMed ID: 12006555
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
    Omura K
    Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.